The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 59 , ISSUE 2 ( April-June, 2017 ) > List of Articles


Shorter Regimen to Treat Multidrug Resistant Tuberculosis and Rifampicin Resistant Tuberculosis

Rajendra Prasad, Amitabh Banka

Citation Information : Prasad R, Banka A. Shorter Regimen to Treat Multidrug Resistant Tuberculosis and Rifampicin Resistant Tuberculosis. Indian J Chest Dis Allied Sci 2017; 59 (2):99-100.

DOI: 10.5005/ijcdas-59-2-99

License: CC BY-NC 4.0

Published Online: 18-11-2022

Copyright Statement:  Copyright © 2017; The Author(s).


PDF Share
  1. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug Resistant Tuberculosis. Geneva: World Health Organization 2014. WHO/HTM/TB/2014.11
  2. World Health Organization. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. May 2012.
  3. Prasad R, Srivastava DK. Multidrug and extensively drug resistant TB (M/XDR TB) management: current issues. Clin Epidemiol Global Health 2013;1:124-8.
  4. Prasad R. Multidrug and extensively drug-resistant tuberculosis management: evidences and controversies. Lung India 2012;29:154-9.
  5. World Health Organization. Global Tuberculosis Report 2016.WHO/HTM/2016.13. Geneva: World Health Organization; 2016.
  6. Prasad R, Gupta N, Singh M. Multidrug resistant tuberculosis: trends and control. Indian J Chest Dis Allied Sci 2014;56;237-46.
  7. Prasad R, Gupta N. MDR and XDR tuberculosis. In: Multidrug Resistant Tuberculosis: Diagnosis and Treatment; 1st edition. New Delhi: Jaypee Brothers Medical Publishers Pvt Ltd;2015: pp 92-111.
  8. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. WHO/HTM/TB/2016.04
  9. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-9.
  10. Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015;19:517-24.
  11. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014;18:1188-94.
  12. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
  13. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful ‘9-month Bangaldesh regimen'for multidrug resistant tuberculosis among over 500 consecutive patients. Int J Tubec Lung Dis 2014;18:1180-87.
  14. Trébucq A, Schwoebel V, Kuaban C, Munogolo ZK, Fikouma V, Bakayoko A, et al. Expanding shortened MDRTB treatment: the West African experience. Int J Tuberc Lung Dis 2014;18 (Suppl. 1); S15.
  15. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014;15:353.
  16. Moodley R, Godec TR; STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016;25:29-35.
  17. World Health Organization. The End TB strategy. Geneva: WHO 2016. WHO/HTM/TB/2015.19. Available at URL: Accessed on: November 20, 2015.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.